Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Receiving a home infusion therapy requiring IV administration of fluid via an indwelling access device for up to 12 hours daily, 7 days a week, for \>4 weeks * Diagnosed with Iron deficiency anemia (Hgb \<11.5 g/dL Female and \<12 g/dL Male) * CHr \<29 pg./mL * Serum Ferritin \<100 ng/mL * TSAT \<20% * Ability and willingness to adhere to the home infusion administration of FPC/Placebo. * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration Exclusion Criteria: * Use of oral or intravenous iron within 4 weeks prior to randomization. * Pregnancy or lactation * Any febrile illness (oral temperature \> 100.4°F, 38°C) during screening. * Treatment with another investigational drug within 30 days of Randomization * Current smoker or tobacco use within ≥3 months * Known cause of anemia other than iron deficiency (e.g., sickle cell disease, thalassemia, pure red cell aplasia, hemolytic anemia, myelodysplastic syndrome, Vitamin B12 deficiency …etc.) * Vitamin deficiency at Screening Visit * Iron overload that contraindicates further iron supplementation as deemed by the PI. * Prior documented hypersensitivity reaction (anaphylaxis) to IV iron administration * History of drug or alcohol abuse within the last 6 months. * Known active tuberculosis, fungal, viral, or parasitic infection requiring anti-microbial therapy or anticipated to require anti-microbial therapy during the patient's participation in this study. * Known positive status for hepatitis B surface antigen (hepatitis B testing is not required as part of this protocol). * Known human immunodeficiency virus (HIV) infection (HIV testing is not required as part of this protocol). * Cirrhosis of the liver based on histological criteria or clinical criteria (e.g., presence of ascites, esophageal varices, spider nevi, or history of hepatic encephalopathy). * Hepatitis C infection if ALT and/or AST levels are consistently greater than twice the upper limit of normal at any time during the 2 months prior to randomization. * Subjects who are anticipated to be unable to complete the entire study (e.g., due to a concurrent disease).